BACKGROUND: Obstructive sleep apnea (OSA) is associated with hypertension. The vasorelaxing peptide adrenomedullin (ADM) may counteract effects of OSA-induced release of vasopressor substances. METHODS: Plasma ADM levels were measured at 9:30 PM, 2:00 AM (after 4 to 5 h of untreated OSA), and 6:00 AM (after 4 h of continuous positive airway pressure treatment) in 15 OSA patients and in 10 controls. RESULTS: Baseline ADM levels were similar in the OSA and control groups (28.7 +/- 6.7 v 27.7 +/- 6.4 pg/mL, respectively), did not change overnight in either group, and were not affected by continuous positive airway pressure. CONCLUSIONS: OSA does not exert any significant acute or chronic effects on plasma ADM levels.
BACKGROUND:Obstructive sleep apnea (OSA) is associated with hypertension. The vasorelaxing peptide adrenomedullin (ADM) may counteract effects of OSA-induced release of vasopressor substances. METHODS: Plasma ADM levels were measured at 9:30 PM, 2:00 AM (after 4 to 5 h of untreated OSA), and 6:00 AM (after 4 h of continuous positive airway pressure treatment) in 15 OSA patients and in 10 controls. RESULTS: Baseline ADM levels were similar in the OSA and control groups (28.7 +/- 6.7 v 27.7 +/- 6.4 pg/mL, respectively), did not change overnight in either group, and were not affected by continuous positive airway pressure. CONCLUSIONS: OSA does not exert any significant acute or chronic effects on plasma ADM levels.
Authors: Colleen Glyde Julian; Andrew W Subudhi; Megan J Wilson; Andrew C Dimmen; Travis Pecha; Robert C Roach Journal: J Appl Physiol (1985) Date: 2011-06-02
Authors: Meropi Karakioulaki; Peter Grendelmeier; Werner Strobel; Thomas Schmid; Kathleen Jahn; Leticia Grize; Michael Tamm; Daiana Stolz Journal: Respir Res Date: 2021-04-20